Replies to post #571377 on NorthWest Biotherapeutics Inc (NWBO)

[biosectinvestor]

So that was a Phase 1/2 trial for another vaccine and DCVax-L of course has already had a Phase 3 trial. Plus NWBO has Flaskworks and will be able to automate and expedite manufacturing and likely improve even further, over time, the efficiency of the automation process.

So no, I do not think NWBO will need to do another Phase 3 for DCVax-L for GBM. That other vaccine will likely need to do a Phase 3 and approval of DCVax-L will likely make raising funds and getting partners for such vaccines a bit easier, though NWBO is so far ahead, that may not help other vaccines a lot unless they partner with NWBO in some manner, maybe for production at its facilities, once NWBO is much further along.

[brooktrail1933]

You do understand this is allogeneic, not autologous. They are taking DCs from OTHER patients, revving them up and then reinjecting them. DCVax-L is an autologous treatment. The DCs are from the patient, are revved up and then reinjected.
Totally different concept.